STOCK TITAN

ProKidney Corp. (PROK) director converts paired units into Class A stock

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ProKidney Corp. director Brian J.G. Pereira reported exchanging paired Class B common stock and ProKidney Holdings, LLC common units into Class A common stock on August 4, 2026. He converted 81,929 paired securities held directly and 675,235 held through the Brian J. G. Pereira 2012 Irrevocable Trust, receiving equal numbers of Class A shares at a stated price of $0.00 per share. The corresponding Class B and LLC common unit interests for these amounts were reduced to zero.

Positive

  • None.

Negative

  • None.
Insider Pereira Brian JG
Role Director
Type Security Shares Price Value
Conversion Class B Common Stock F1, F2 81,929 $0.00 $0.00
Conversion Common Units in ProKidney Holdings, LLC F3 81,929 $0.00 $0.00
Conversion Class B Common Stock F1, F2 675,235 $0.00 $0.00
Conversion Common Units in ProKidney Holdings, LLC F3 675,235 $0.00 $0.00
Conversion Class A Common Stock 81,929 $0.00 $0.00
Conversion Class A Common Stock 675,235 $0.00 $0.00
Holdings After Transaction: Class B Common Stock — 0 shares (Direct); Common Units in ProKidney Holdings, LLC — 0 shares (Direct); Class B Common Stock — 0 shares (Indirect, By Brian J. G. Pereira 2012 Irrevocable Trust); Common Units in ProKidney Holdings, LLC — 0 shares (Indirect, By Brian J. G. Pereira 2012 Irrevocable Trust); Class A Common Stock — 81,929 shares (Direct); Class A Common Stock — 675,235 shares (Indirect, By Brian J. G. Pereira 2012 Irrevocable Trust)
Footnotes (3)
  1. F1. The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis.
  2. F2. The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire.
  3. F3. The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.
Direct paired securities converted 81,929 shares Class B Common Stock and LLC Common Units exchanged into Class A Common Stock
Indirect paired securities converted 675,235 shares Held by Brian J. G. Pereira 2012 Irrevocable Trust, exchanged into Class A
Direct Class A holdings after conversion 81,929 shares Class A Common Stock held directly by Brian J.G. Pereira following transactions
Indirect Class A holdings after conversion 675,235 shares Class A Common Stock held via Brian J. G. Pereira 2012 Irrevocable Trust
Derivative securities converted 1,514,328 Total derivative shares in conversion transactions per transaction summary
Stated conversion price $0.00 per share Price per share for all reported conversions
paired securities financial
"The shares of Class B Common Stock and the Common Units ... are paired securities."
Business Combination Agreement financial
"received pursuant to the terms of the Business Combination Agreement by and between the Issuer"
A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.
Common Units in ProKidney Holdings, LLC financial
"The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC"
Amended and Restated Exchange Agreement financial
"subject to the limitations set forth in the Amended and Restated Exchange Agreement"
Limited Liability Company Agreement financial
"the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC"
A limited liability company agreement is the legal contract that lays out who owns a limited liability company, how it is run, how profits and losses are shared, and the rules for major decisions, transfers and exits. For investors it functions like an operating manual or roadmap: it determines control rights, payout priority, dispute resolution and protections against personal liability, so it directly affects risk, governance and how and when investors can realize returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did PROK director Brian J.G. Pereira report in this Form 4?

Brian J.G. Pereira reported converting paired Class B common stock and LLC common units into Class A common stock on August 4, 2026. He exchanged 81,929 securities held directly and 675,235 held via a 2012 irrevocable trust for equal numbers of Class A shares.

How many ProKidney (PROK) Class A shares did Brian J.G. Pereira receive?

Brian J.G. Pereira received 81,929 Class A shares directly and 675,235 Class A shares indirectly through the Brian J. G. Pereira 2012 Irrevocable Trust. Each Class B share paired with a Common Unit was exchanged on a one-for-one basis for Class A stock.

Were Brian J.G. Pereira’s PROK transactions made under a Rule 10b5-1 trading plan?

The transactions were not reported as made under a Rule 10b5-1 plan; the related checkbox was left unchecked. No footnote indicates any separate pre-arranged trading arrangement, so the conversions appear as discretionary exchanges of paired securities into Class A shares.

What are the paired securities mentioned in the ProKidney (PROK) Form 4?

The paired securities are shares of Class B Common Stock and Common Units in ProKidney Holdings, LLC. According to the disclosure, each Class B share together with a paired Common Unit may be exchanged for one share of Class A Common Stock, subject to specified agreements.

Did Brian J.G. Pereira retain ProKidney (PROK) derivative interests after these conversions?

For the reported positions, the Class B shares and Common Units converted by Pereira now show zero securities remaining following the transactions. His resulting holdings consist of 81,929 Class A shares directly and 675,235 Class A shares indirectly through the 2012 irrevocable trust.

How many derivative securities were converted in this ProKidney (PROK) Form 4?

The filing shows 1,514,328 derivative securities involved in conversion transactions, based on the transaction summary. These represent paired Class B common stock and ProKidney Holdings, LLC Common Units exchanged into Class A common stock at a stated conversion price of $0.00 per unit.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pereira Brian JG

(Last)(First)(Middle)
C/O PROKIDNEY CORP
2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)
WINSTON SALEM NORTH CAROLINA 27103

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/04/2026C81,929A$081,929D
Class A Common Stock08/04/2026C675,235A$0675,235IBy Brian J. G. Pereira 2012 Irrevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Class B Common Stock(1)$008/04/2026C81,929 (2) (2)Class A Common Stock81,929$00D
Common Units in ProKidney Holdings, LLC$008/04/2026C81,929 (3) (3)Class A Common Stock81,929$00D
Class B Common Stock(1)$008/04/2026C675,235 (2) (2)Class A Common Stock675,235$00IBy Brian J. G. Pereira 2012 Irrevocable Trust
Common Units in ProKidney Holdings, LLC$008/04/2026C675,235 (3) (3)Class A Common Stock675,235$00IBy Brian J. G. Pereira 2012 Irrevocable Trust
Explanation of Responses:
1. The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis.
2. The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire.
3. The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.
/s/ Todd Girolamo, attorney in fact08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)